A two-process theory of schizophrenia: Evidence from studies in post-mortem brain

Journal of Psychiatric Research

Volumn 31, Issue 2, 1997, Pages 277-295

  Deakin, J F W ^a   Simpson, M D C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GLUTAMATE RECEPTOR; GLUTAMIC ACID; NEUROLEPTIC AGENT;

ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN DEVELOPMENT; DRUG EFFICACY; FRONTAL CORTEX; GABAERGIC SYSTEM; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; NERVE PROJECTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TEMPORAL CORTEX; TEMPORAL LOBE;

EID: 0030743151     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3956(96)00042-8     Document Type: Article

References (130)

1. Akbarian, S., Huntsman, M. M., Kim, J. J., Tafazzoli, A., Potkin, S. G., Bunney, W. E., & Jones, E. G. (1995). GABA(A) receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cerebral Cortex, 5(6), 550-560.
2. Akbarian, S., Kim, J. J., Potkin, S. G., Hagman, J. O., Tafazzoli, A., Bunney, W. E. Jr, Jones, E. G. (1995). Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archives of General Psychiatry, 52, 258-266.
3. Arnold, S. E., Franz, B. R., Gur, R. C., Gur, R. E., Shapiro, R. M., Moberg, P. J., & Trojanowski, J. Q. (1995). Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. American Journal of Psychiatry, 152, 738-748.
4. 2) receptor binding in the frontal cortex of schizophrenic patients. Journal of Neural Transmission, 85, 19-29.
5. Benes, F. M., Davidson, J., & Bird, E. D. (1986). Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Archives of General Psychiatry, 43, 31-35.
6. Benes, F. M., McSparren, J., Bird, E. D., SanGiovanni, J. P., & Vincent, S. L. (1991). Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Archives of General Psychiatry, 48, 996-1001.
7. Benes, F. M., Sorensen, I., & Bird, E. D. (1991). Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophrenia Bulletin, 17, 597-608.
8. Benes, F. M., Sorensen, I., Vincent, S. L., Bird, E. D., & Sathi, M. (1992). Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cerebral Cortex, 2, 503-512.
9. Benes, F. M., Vincent, S. L., Alsterberg, G., Bird, E. D., & SanGiovanni, J. P. (1992). Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. Journal of Neuroscience, 12, 924-929.
10. Bennett, J. P., Jr, Enna, S. J., Bylund, D. B., Gillin, J. C., Wyatt, R. J., & Snyder, S. H. (1979). Neurotransmitter receptors in frontal cortex of schizophrenics. Archives of General Psychiatry, 36, 927-934.
11. Bird, E. D., Spokes, E. G., Barnes, J., MacKay, A. V., Iversen, L. L., & Shepherd, M. (1977). Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet, 2, 1157-1158.
12. Bird, E. D., Spokes, E. G., Barnes, J., Mackay, A. V. P., Iversen, L. L., & Shepherd, M. (1978). Glutamic-acid decarboxylase in schizophrenia. Lancet, i, 156.
13. Bird, E. D., Spokes, E. G., & Iversen, L. L. (1979). Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain, 102, 347-360.
14. 3H]-GABA in nerve terminals of rat cerebral cortex by electron microscope autoradiography. Nature, 229, 628-630.
15. Bogerts, B. (1993). Recent advances in the neuropathology of schizophrenia. Schizophrenia Bulletin, 19, 431-445.
16. Breese, C. R., Freedman, R., & Leonard, S. S. (1995). Glutamate receptor subtype expression in human post-mortem brain tissue from schizophrenics and alcohol abusers. Brain Research, 674, 82-90.
17. Buchsbaum, M. S. (1990). The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophrenia Bulletin, 16, 379-389.
18. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology, in press.
19. Carlsson, M., & Carlsson, A. (1990). Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bulletin, 16, 425-432.
20. Cascella, N. G., Macciardi, F., Cavallini, C., & Smeraldi, E. (1994). d-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. Journal of Neural Transmission, 95, 105-111.
21. Chakos, M. H., Lieberman, J. A., Bilder, R. M., Borenstein, M., Lerner, G., Bogerts, B., Wu, H., Kinon, B., & Ashtari, M. (1994). Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry, 151, 1430-1436.
22. Christison, G. W., Casanova, M. F., Weinberger, D. R., Rawlings, R., & Kleinman, J. E. (1989). A quantitative investigation of hippocampal pyramidal cell size, shape, and variability of orientation in schizophrenia. Archives of General Psychiatry, 46, 1027-1032.
23. Costa, J., Khaled, E., Sramek, J., Bunney, W. Jr, Potkin, S. G. (1990). An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics. Journal of Clinical Psychopharmacology, 10, 71-72.
24. Crino, P. B., Vogt, B. A., Volicer, L., & Wiley, R. G. (1990). Cellular localization of serotonin 1A, 1B and uptake sites in cingulate cortex of the rat. Journal of Pharmacology and Experimental Therapeutics, 252, 651-656.
25. Cross, A. J., Crow, T. J., & Owen, F. (1979). Gamma-aminobutyric acid in the brain in schizophrenia. Lancet, I, 560-561.
26. Cross, A. J., Crow, T. J., Ferrier, I. N., Johnson, J. A., Johnstone, E. C., Owen, F., Owens, D. G. & Poulter, M. (1985). Chemical and structural changes in the brain in patients with movement disorder. In J. Casey, D. E. Casey, T. N. Chase, A. V. Christensen and J. Gerlach (Eds), Dyskinesia-Research and Treatment. Psychopharmacology Supplementum 2 (pp. 104-110). Berlin: Springer Verlag Press.
27. Crow, T. J., Owen, F., Cross, A. J., Lofthouse, R., & Longden, A. (1978). Brain biochemistry in schizophrenia [Letter]. Lancet, 1, 36-37.
28. Crow, T. J., Macmillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986). A randomized controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 120-127.
29. Davidson, M., Powchik, P., Gabriel, S. M., Haroutunian, V., Harvey, P. D., & Davis, K. L. (1995). Correlations between temporal lobe synaptic protein immunoactivity and schizophrenic psychosis. Schizophrenia Research, 15, 26.
30. Deakin, J. F. W. (1994). Neuropsychological implications of brain changes in schizophrenia: an overview. Psychopathology, 27, 251-254.
31. Deakin, J. F. W., Slater, P., Simpson, M. D. C., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P., & Cross, A. J. (1989). Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. Journal of Neurochemistry, 52, 1781-1786.
32. Deakin, J. F. W., Slater, P., Simpson, M. D. C., & Royston, M. C. (1990). Hyperinnervation of orbital frontal cortex in schizophrenia. British Journal of Psychiatry, 157, 459-605.
33. Delisi, L. E., Tew, W., Hoff, A. L., Sakuma, M., Kushner, M., Lee, G., Shedlack, K., Smith, A. M., & Grimson, R. (1996). A prospective follow-up study of brain morphology and cognition in first episode schizophrenic patients-preliminary findings. Biological Psychiatry, 38, 349-360.
34. Deutsch, S. I., Mastropaolo, J., Schwartz, B. L., Rosse, R. B., & Morihisa, J. M. (1989). A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clinical Neuropharmacology, 12, 1-13.
35. Deveney, A. M., Murray, A. M., Hyde, T. M., Herman, M. M., & Kleinman, J. E. (1995). GABA-A receptor binding changes in schizophrenia: dorsolateral prefrontal and cingulate cortices. Society for Neuroscience Abstracts, 21, 835-6.
36. Domino, E. F. (1980). History & pharmacology of PCP and PCP-related analogs. Journal of Psychedelic Drugs, 12, 223-227.
37. Eastwood, S. L., McDonald, B., Burnet, P. W., Beckwith, J. P., Kerwin, R. W., & Harrison, P. J. (1995). Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Research Molecular Brain Research, 29, 211-223.
38. Elkashef, A. M., Buchanan, R. W., Gellad, F., Munson, R. C., & Breier, A. (1994). Basal ganglia pathology in schizophrenia and tardive dyskinesia: an MRI quantitative study. American Journal of Psychiatry, 151, 752-755.
39. Falkai, P., & Bogerts, B. (1986). Cell loss in the hippocampus of schizophrenics. European Archives of Psychiatry and Neurological Science, 236, 154-161.
40. 11C]raclopride. Archives of General Psychiatry, 47, 213-219.
41. Fonnum, F. (1984). Glutamate a neurotransmitter in mamalian brain. Journal of Neurochemistry, 42, 1-11.
42. Francis, P. T., Pangalos, M. N., Pearson, R. C. A., Middlemiss, D. N., Stratmann, G. C., Bowen, D. M. (1992) 5-hydroxytryptamine-1A but not 5-hydroxytryptamine-2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. Journal of Pharmacology and Experimental Therapeutics, 261, 1273-1281.
43. Friston, K. J., Liddle, P. F., Frith, C. D., Hirsch, S. R., & Frackowiak, R. S. (1992). The left medial temporal region and schizophrenia. A PET study. Brain, 115, 367-382.
44. Garbutt, J. C., & van Kammen, D. P. (1983). The interaction between GABA and dopamine: implications for schizophrenia. Schizophrenia Bulletin, 9, 336-353.
45. Gattaz, W. F., Gattaz, D., & Beckmann, H. (1982). Glutamate in schizophrenics and healthy controls. Archiv. Psychiatr. Nervenkr., 231, 221-225.
46. Gattaz, W. F., Gasser, T., & Beckmann, H. (1985). Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biological Psychiatry, 20, 360-366.
47. Goff, D. C., Tsai, G., Manoach, D. S., & Coyle, J. T. (1995). Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. American Journal of Psychiatry, 152, 1213-1215.
48. 3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sciences, 40, 259-266.
49. Harrison, P. J., McLaughlin, D. P., & Kerwin, R. W. (1991). Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet, 337, 450-452.
50. Harvey, I., Persaud, R., Ron, M. A., Baker, G., & Murray, R. M. (1994). Volumetric MRI measurements in bipolars compared with schizophrenics and healthy controls. Psychological Medicine, 24, 689-699.
51. 1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sciences, 48, 355-363.
52. Heckers, S., Heinsen, H., Geiger, B., & Beckmann, H. (1991). Hippocampal neuron number in schizophrenia. A stereological study. Archives of General Psychiatry, 48, 1002-1008.
53. Hellewell, J. S. E., & Deakin, J. F. W. (1994). Impaired frontal lobe function in schizophrenia is familial. Schizophrenia Research, 11, 149.
54. Horton, K., Forsyth, C. S., Sibtain, N., Bruton, C. J., Royston, M. C., & Roberts, G. W. (1993). Synaptophysin: a test of the etiological hypotheses. Schizophrenia Research, 9, 149.
55. Humphries, C. R., Virgo, L., Mortimer, A., Barnes, T., Hirsch, S., & de Belleroche, J. (1995). The expression of the N-methyl-D-aspartate receptor subunit NR-1 is decreased in schizophrenia. Schizophrenia Research, 15, 60.
56. Ishimaru, M., Kurumaji, A., & Toru, M. (1992). NMDA-associated glycine binding site increases in schizophrenic brains [letter]. Biological Psychiatry, 32, 379-381.
57. Ishimaru, M., Kurumaji, A., & Toru, M. (1994). Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biological Psychiatry, 35, 84-95.
58. Javitt, D. C. (1987). Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside Journal of Clinical Psychiatry, 9, 12-35.
59. Javitt, D. C., Zylberman, I., Zukin, S. R., Heresco-Levy, U., & Lindenmayer, J. P. (1994). Amelioration of negative symptoms in schizophrenia by glycine. American Journal of Psychiatry, 151, 1234-1236.
60. Jeste, D. V., & Lohr, J. B. (1989). Hippocampal pathologic findings in schizophrenia. A morphometric study. Archives of General Psychiatry, 46, 1019-1024.
61. Joyce, J. N., Shane, A., Lexow, N., Winokur, A., Casanova, M. F., & Kleinman, J. E. (1993). Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology, 8, 315-336.
62. Kerwin, R. W., Patel, S., Meldrum, B. S., Czudek, C., & Reynolds, G. P. (1988). Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet, 1, 583-584.
63. Kerwin, R. W., Patel, S., & Meldrum, B. S. (1990). Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience, 39, 25-32.
64. Keshavan, M. S., Bagwell, W. W., Haas, G. L., Sweeney, J. A., Schooler, N. R., & Pettegrew, J. W. (1994). Changes in caudate volume with neuroleptic administration. Lancet, 344, 1434.
65. Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmuller, B. (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neuroscience Letters, 20, 379-382.
66. Kiuchi, Y., Kobayashi, T., Takeuchi, J., Shimizu, H., & Ogata, H., Toru, M. (1989). Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. European Archives of Psychiatry and Neurological Science, 239, 71-78.
67. Kleinman, J. E., Laruelle, M., Joyce, J. N., & Casanova, M. F. (1992). Abnormalities of serotonergic neural transmission in prefrontal cortex in schizophrenia. Clinical Neuropharmacology, 15(Suppl 1 Pt A), 397A-398A.
68. Kornhuber, J., Mack-Burkhardt, F., Riederer, P., Hebenstreit, G. F., Reynolds, G. P., Andrews, H. B., & Beckmann, H. (1989). [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. Journal of Neural Transmission, 77, 231-236.
69. Korpi, E. R., Kaufmann, C. A., Marnela, K. M., & Weinberger, D. R. (1987). Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Research, 20, 337-345.
70. Korpi, E. R., Kleinman, J. E., Goodman, S. I., & Wyatt, R. J. (1987). Neurotransmitter amino acids in post-mortem brains of chronic schizophrenic patients. Psychiatry Research, 22, 291-301.
71. Kovelman, J. A., & Scheibel, A. B. (1984). A neurohistological correlate of schizophrenia. Biological Psychiatry, 19, 1601-1621.
72. 3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of chronic schizophrenics. Journal of Neurochemistry, 59, 829-837.
73. Kutay, F. Z., Pogun, S., Hariri, N. I., Peker, G., & Erlacin, S. (1989). Free amino acid level determinations in normal and schizophrenic brain. Progress in Neuropsychopharmacology and Biological Psychiatry, 13, 119-126.
74. Laruelle, M., Abi-Dargham, A., Casanova, M. F., Toti, R., Weinberger, D. R., & Kleinman, J. E. (1993). Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Archives of General Psychiatry, 50, 810-818.
75. Lewis, S. W., & Murray, R. M. (1987). Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia. Journal of Psychiatric Research, 21, 413-421.
76. Liddle, P. F., Spence, S. A., Sharma, T., Hellewell, J. S. E., McGuire, P., Deakin, J. F. W., Murray, R. M., Friston, K. J., & Frith, C. D. (1995). A PET study of obligate carriers of the predisposition to schizophrenia. Schizophrenia Research, 15, 90.
77. Loebel, M. D., Lieberman, J. A., Alvir, J. M. J., Mayerhoff, D. I., Geisler, S. H., & Szymanski, S. R. (1992). Duration of psychosis and outcome in first-episode schizophrenia. American Journal of Psychiatry, 149, 1183-1188.
78. 3H]AMPA binding in frontal cortex in schizophrenia. Schizophrenia Research, 11, 121.
79. Mackay, A. V., Iversen, L. L., Rossor, M., Spokes, E., Bird, E., Arregui, A., Creese, I., & Synder, S. H. (1982). Increased brain dopamine and dopamine receptors in schizophrenia. Archives of General Psychiatry, 39, 991-997.
80. McEvedy, C. J. B., & Everall, I. (1995). A morphometric study of the frontal lobe in schizophrenia. Schizophrenia Research, 15, 30.
81. McEvoy, J. P., Schooler, N. R., & Wilson, W. H. (1991). Predictors of therapeutic response to haloperidol in first episode schizophrenia. Psychopharmacology Bulletin, 27, 97-101.
82. McGeer, E. & McGeer, P. (1979). GABA-containing neurons in schizophrenia. Huntingdon's chorea and normal aging. In P. Krogsgaard-Larsen, J. Scheel-Kruger and H. Kofod (Eds), GABA-Neurotransmitters: Pharmacochemical, Biochemical and Phamacological Aspects (pp. 240-256). Copenhagen: Munksgaard.
83. 2 receptors in chronic schizophrenics. Biological Psychiatry, 21, 1407-1414.
84. Nakai, T., Hashimoto, T., Kitamura, N., Nishino, N., Shirakawa, O., Hanada, S., Mita, T., & Tanaka, C. (1988). Alterations of neurotransmitter receptors in schizophrenic patients. Psychopharmacology, 96(Suppl), 187.
85. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neuroscience Letters, 40, 245-250
86. Owen, F. & Simpson, M. D. C. (1995). The neurochemistry of schizophrenia. In S. R. Hirsch and D. R. Weinberger (Eds), Schizophrenia (pp. 358-378). Oxford, UK: Blackwell Science Ltd.
87. Owen, F., Cross, A. J., Crow, T. J., Longden, A., Poulter, M., & Riley, G. J. (1978). Increased dopamine-receptor sensitivity in schizophrenia. Lancet, 2, 223-225.
88. Owen, F., Crow, T. J., & Poulter, M. (1987). Central dopaminergic mechanisms in schizophrenia. Acta Psychiatrica Belg., 87, 552-565.
89. Perry, E. K., Blessed, G., Perry, R. H., & Tomlinson, B. E. (1978). Brain biochemistry in schizophrenia [Letter]. Lancet, 1, 35-36.
90. Perry, T. L. (1982). Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neuroscience Letters, 28, 81-85.
91. Perry, T. L., Kish, S. J., Buchanan, J., & Hansen, S. (1979). Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet, 1, 237-239.
92. Perry, T. L., Hansen, S., & Jones, K. (1989). Schizophrenia, tardive dyskinesia, and brain GABA. Biological Psychiatry, 25, 200-206.
93. Powchik, P., Davidson, M., Gabriel, S. M., Haroutunian, V., Harvey, P. D., & Davis, K. L. (1995). Somatostatin and NPY deficits in schizophrenic cortex. Schizophrenia Research, 15, 26.
94. Prieto-Rincon, D., Pinerua-Shuhaibar, L., Bonilla, E., Prasad, A., & Arrieta, A. (1991). Paranoid schizophrenia: free amino acids in the cerebrospinal fluid. Invest. Clin., 32, 149-155.
95. Reynolds, G. P. (1983). Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature, 305, 527-529.
96. Reynolds, G. P. (1989). Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia. British Journal of Psychiatry, 155, 305-316.
97. Reynolds, G. P. (1991). Amino acid transmitters and dopamine function in the brain in schizophrenia. In G. Racagni, N. Brunello & T. Fokuda (Eds), Biological Psychiatry (pp. 491-494). Amsterdam: Excerpta Medica.
98. Reynolds, G. P., & Cutts, A. J. (1994). Regionally specific subcortical glutamatergic deficits in schizophrenia. Schizophrenia Research, 11, 122.
99. Reynolds, G. P., & Mason, S. L. (1994). Are striatal dopamine D4 receptors increased in schizophrenia? Journal of Neurochemistry, 63, 1576-1577.
100. Reynolds, G. P., & Stroud, D. (1993). Hippocampal benzodiazepine receptors in schizophrenia. Journal of Neural Transmission, 93, 151-155.
101. 2 receptors and their involvement in schizophrenia and neuroleptic drug action. Journal of Neural Transmission Supplement, 18, 273-277.
102. Reynolds, G. P., Czudek, C., & Andrews, H. B. (1990). Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biological Psychiatry, 27, 1038-1044.
103. Reynolds, G. P., Cutts, A. J., & Mason, S. L. (1993). Temporal, but not frontal, cortical glutamatergic deficits in schizophrenia. Schizophrenia Research, 9, 150.
104. Reynolds, I. J., & Miller, R. J. (1990). Allosteric modulation of N-methyl-D-aspartate receptors. Advances in Pharmacology, 21, 101-126.
105. Roberts, D. A., Balderson, D., Pickering-Brown, S. M., Deakin, J. F. W. & Owen, F. (1996). The abundance of dopamine D4 receptor mRNA in post-mortem brains of schizophrenics and controls. Schizophrenia Research, in press.
106. Roberts, E. (1972). A hypothesis suggesting that there is a defect in the GABA system in schizophrenia. Neuroscience Research Program Bulletin, 10, 468-482.
107. Rosse, R. B., Schwartz, B. L., Davis, R. E., & Deutsch, S. I. (1991). An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clinical Neuropharmacology, 14, 268-272.
108. Seeman, P., Guan, H. C., & Van Tol, H. H. (1993). Dopamine D4 receptors elevated in schizophrenia. Nature, 365, 441-445.
109. Selemon, L. D., Rajkowska, G., Goldman-Rakic, P. S. (1995). Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Archives of General Psychiatry, 52, 805-818.
110. Sherif, F., Eriksson, L., & Oreland, L. (1992). Gamma-aminobutyrate aminotransferase activity in brains of schizophrenic patients. Journal of Neural Transmission, 90, 231-240.
111. Sherman, A. D., Davidson, A. T., Baruah, S., Hegwood, T. S., & Waziri, R. (1991). Evidence of glutamatergic deficiency in schizophrenia. Neuroscience Letters. 121, 77-80.
112. Simpson, M. D. C., Slater, P., Deakin, J. F. W., Royston, M. C., & Skan, W. J. (1989). Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neuroscience Letters, 107, 211-215.
113. Simpson, M. D. C., Slater, P., Royston, M. C., & Deakin, J. F. W. (1991). Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophrenia Research, 6, 41-48.
114. Simpson, M. D. C., Royston, M. C., Slater, P., & Deakin, J. F. W. (1992). Neurochemical abnormalities of the cerebral cortex in schizophrenia. Schizophrenia Research, 6, 133-134.
115. Simpson, M. D. C., Slater, P., Royston, M. C., & Deakin, J. F. W. (1992). Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Research, 42, 273-282.
116. 3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia. Biological Psychiatry, in press.
117. Slater, P., McConnell, S., Dsouza, S. W., Barson, A. J., Simpson, M. D. C., & Gilchrist, A. C. (1992). Age-related changes in binding to excitatory amino acid uptake site in temporal cortex of human brain. Developmental Brain Research, 65(2), 157-160.
118. 3H]-MK-801 binding in human temporal cortex. British Journal of Pharmacology, 108, 1143-1149.
119. Spokes, E. G., Garrett, N. J., Rossor, M. N., & Iversen, L. L. (1980). Distribution of GABA in post-mortem brain tissue from control, psychotic and Huntington's chorea subjects. J. Neurol. Sci., 48, 303-313.
120. 3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glutamatergic neurons associated with major psychoses? Neurochemical Research, 18, 219-223.
121. Steit, P. (1984). Glutamate and aspartate as transmitter candidates for systems of the cerebral cortex. In E. G. Jones & A. Peters (Eds), Cerebral cortex (pp. 119-143). New York: Plenum Press.
122. Suddath, R. L., Casanova, M. F., Goldberg, T. E., Daniel, D. G., Kelsoe, J. R. Jr, Weinberger, D. R. (1989). Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. American Journal of Psychiatry, 146, 464-472.
123. 3H-MK801 binding sites in post-mortem brains of chronic schizophrenic patients. Procedings of the Collegium Internationale Neuro-Psychopharmacologium 17th, 2, 28.
124. Toru, M., Watanabe, S., Shibuya, H., Nishikawa, T., Noda, K., Mitsushio, H., Ichikawa, H., Kurumaji, A., Takashima, M., Mataga, N., & Ogawa, A. (1988). Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatrica Scandinavica, 78, 121-137.
125. Waddington, J. L., Youssef, H. A., Kinsella, A. (1995). Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychological Medicine, 25, 849-857.
126. Weinberger, D. R. (1995). From neuropathology to neurodevelopment. Lancet, 346, 552-557.
127. Weinberger, D. R., Berman, K. F., Suddath, R., Torrey, E. F. (1992). Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. American Journal of Psychiatry, 149, 890-897.
128. Weissman, A. D., Casanova. M. F., Kleinman, J. E., London, E. D., & De Souza, E. B. (1991). Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biological Psychiatry, 29, 41-54.
129. Whitaker, P. M., Crow, T. J., & Ferrier, I. N. (1981). Tritiated LSD binding in frontal cortex in schizophrenia. Archives of General Psychiatry, 38, 278-280.
130. Zipursky, R. B., Marsh, L., Lim, K. O., DeMent, S., Shear, P. K., Sullivan, E. V., Murphy, G. M., Csernansky, J. G., & Pfefferbaum, A. (1994). Volumetric MRI assessment of temporal lobe structures in schizophrenia. Biological Psychiatry, 35, 501-516.